Skip to main content

Table 1 Characteristics of included studies

From: Treatment with LABA versus LAMA for stable COPD: a systematic review and meta-analysis

study

Treatment (μg)

Number of subjects

Duration

(weeks)

Key inclusion criteria

Male (%)

Mean age (years)

Baseline

FEV1

(%predicted)

Donohue 2002

Tiotoropium 18

Salmeterol 100

623

24

%FEV1 < 60%

>  40 yrs., > 10PY

74.6

64.0

40.2

Brusasco 2003

Tiotoropium 18

Salmeterol 100

807

24

%FEV1 ≤ 65%,

>  40 yrs., > 10PY

76.2

64.0

42.9

Briggs 2005

Tiotoropium 18

Salmeterol 100

653

12

%FEV1 < 60%,

>  40 yrs., > 10PY

66.4

64.4

37.7

Buhl 2011

INTENSITY study

Tiotoropium 18

Indacaterol 150

1598

12

%FEV1 30–80%,

>  40 yrs., > 10PY

69.0

63.5

54.4

Vogelmeier 2011

POET study

Tiotoropium 18

Salmeterol 100

7376

52

%FEV1 ≤ 70%,

≥ 40 yrs., ≥ 10PY, Ex (+)

74.6

62.9

49.3

Bateman 2013

SHINE study

Glycopyrronium 50a

Indacaterol 150a

1435

26

%FEV1 ≥ 30%, <  80%

≥ 40 yrs., ≥ 10PY

75.4

63.9

53.7

Decramer 2013

INVIGORATE

Tiotoropium 18

Indacaterol 150

3439

52

%FEV1 > 30%, ≤ 50%

≥ 40 yrs., ≥ 10PY, Ex (+)

77.0

64.0

40.5

Donohue 2013

Umeclidinium 62.5a

Vilanterol 25a

839

24

%FEV1 ≤ 70%

mMRC ≥2, ≥ 40 yrs., ≥ 10PY

69.0

63.3

47.5

Celli 2014

Umeclidinium 125a

Vilanterol 25a

811

24

%FEV1 ≤ 70%

mMRC ≥2, ≥ 40 yrs., ≥ 10PY

66.0

63.0

48.7

Decramer 2014

Tiotoropium 18a

Vilanterol 25a

417

24

%FEV1 ≤ 70%

mMRC ≥2, ≥ 40 yrs., ≥ 10PY

68.0

62.9

47.7

D’Urzo 2014

AUGMENT study

Aclidinium 800a

Formoterol 24a

669

24

%FEV1 ≥ 30%, <  80%

mMRC ≥2, ≥ 40 yrs., > 10PY

56.0

64.2

53.3

Singh 2014

ACLIFORM-COPD

Aclidinium 800a

Formoterol 24a

769

24

%FEV1 < 70%

mMRC ≥2, ≥ 40 yrs., > 10PY

66.5

63.2

54.0

Buhl 2015

TOnado 1 and 2

Tiotoropium 2.5/5a

Olodaterol 5a

2071

52

%FEV1 > 30%, <  80%

mMRC ≥2, ≥ 40 yrs., > 10PY

73.4

64.1

50.0

Mahler 2015

FLIGHT1 and 2

Glycopyrrolate 31.2a Indacaterol 55a

1022

12

%FEV1 > 30%, <  80%

mMRC ≥2, ≥ 40 yrs., > 10PY

64.8

63.6

54.5

Mahler 2016

GEM3 study

glycopyrrolate 31.2

Indacaterol 75

511

52

%FEV1 ≥ 30%, <  80%

mMRC> 2, ≥ 40 yrs., ≥ 10PY

57.2

63.2

53.1

D’Urzo 2017

AUGMENT study

Aclidinium 800a

Formoterol 24a

669

52

%FEV1 ≥ 30%, <  80%

≥ 40 yrs., ≥ 10PY

56.0

64.2

53.3

Hanania 2017

PINNACLE-3

Glycopyrronium 36a

Formoterol 19.2a

1772

52

%FEV1 ≥ 30%, <  80% or

%FEV1 < 30% & FEV1 ≥ 750 ml, 40–80 yrs

55.8

62.8

51.3

Martinez 2017

PINNACLE-1, −2

Glycopyrronium 36a

Formoterol 19.2a

1776

24

%FEV1 ≥ 30%, <  80% or

%FEV1 < 30% & FEV1 ≥ 750 ml, 40–80 yrs

55.8

62.8

51.3

Lipworth 2018

PINNACLE-4

Glycopyrronium 36a

Formoterol 19.2a

954

24

%FEV1 < 80%

40–80 yrs., ≥ 10PY

74.1

64.1

54.4

  1. Definition of abbreviations: FEV1 forced expiratory volume in 1 s, yrs years, PY pack-years
  2. Ex(+): at least one exacerbation in the previous year; mMRC: modified Medical Research Council dyspnoea scale
  3. aindividual components of subgroup analysis in comparison of LAMA/LABA combination therapy